Celgene Pulls Back From First-Line CLL As Revlimid ORIGIN Trial Terminates

Imbalance of deaths for Revlimid in the ORIGIN treatment-naïve CLL study could be due to the advanced age of participants or their many comorbidities. Future of drug as monotherapy in treatment-naïve patients is now unlikely, but studies in later lines of treatment go on.